{"doi":"10.3310\/hta13110","coreId":"195645","oai":"oai:lra.le.ac.uk:2381\/7750","identifiers":["oai:lra.le.ac.uk:2381\/7750","10.3310\/hta13110"],"title":"Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation","authors":["Tappenden, Paul","Jackson, R.","Cooper, K.","Rees, A.","Simpson, E.","Read, R.","Nicholson, Karl G."],"enrichments":{"references":[],"documentType":{"type":0}},"contributors":[],"datePublished":"2009-02","abstract":"Objectives: To evaluate the clinical effectiveness\\ud\nand incremental cost-effectiveness of amantadine,\\ud\noseltamivir and zanamivir for seasonal and postexposure\\ud\nprophylaxis of influenza.\\ud\nData sources: A MEDLINE search strategy was used\\ud\nand searches were carried out in July 2007.\\ud\nReview methods: An independent health economic\\ud\nmodel was developed based on a review of existing\\ud\ncost-effectiveness models and clinical advice. The model\\ud\ndraws together a broad spectrum of evidence relating\\ud\nto the costs and consequences associated with influenza\\ud\nand its prevention. Where direct evidence concerning\\ud\nthe effectiveness of prophylaxis within specific model\\ud\nsubgroups was lacking, the model uses estimates from\\ud\nmixed subgroups or extrapolates from other mutually\\ud\nexclusive subgroups.\\ud\nResults: Twenty-six published references relating to 22\\ud\nrandomised controlled trials (RCTs) were included in the\\ud\nclinical effectiveness review, along with one unpublished\\ud\nreport. Eight, six and nine RCTs were included for\\ud\namantadine, oseltamivir and zanamivir respectively.\\ud\nThe study quality was variable and gaps in the evidence\\ud\nbase limited the assessment of the clinical effectiveness\\ud\nof the interventions. For seasonal prophylaxis, there\\ud\nwas limited evidence for the efficacy of amantadine in\\ud\npreventing symptomatic, laboratory-confirmed influenza\\ud\n(SLCI) in healthy adults [relative risk (RR) 0.40, 95%\\ud\nconfidence interval (CI) 0.08\u20132.03]. Oseltamivir was\\ud\neffective in preventing SLCI, particularly when used in\\ud\nat-risk elderly subjects (RR 0.08, 95% CI 0.01\u20130.63).\\ud\nThe preventative efficacy of zanamivir was most notable\\ud\nin at-risk adults and adolescents (RR 0.17, 95% CI 0.07\u2013\\ud\n0.44), and healthy and at-risk elderly subjects (RR 0.20,\\ud\n95% CI 0.02\u20131.72). For post-exposure prophylaxis,\\ud\ndata on the use of amantadine were again limited: in\\ud\nadolescents an RR of 0.10 (95% CI 0.03\u20130.34) was\\ud\nreported for the prevention of SLCI. Oseltamivir was\\ud\neffective in households of mixed composition (RR\\ud\n0.19, 95% CI 0.08\u20130.45). The efficacy of zanamivir in\\ud\npost-exposure prophylaxis within households was also\\ud\nreported (RR 0.21, 95% CI 0.13\u20130.33). Interventions\\ud\nappeared to be well tolerated. Limited evidence was\\ud\navailable for the effectiveness of the interventions in\\ud\npreventing complications and hospitalisation and in\\ud\nminimising length of illness and time to return to normal\\ud\nactivities. No clinical effectiveness data were identified\\ud\nfor health-related quality of life or mortality outcomes.\\ud\nWith the exception of at-risk children, the incremental\\ud\ncost\u2013utility of seasonal influenza prophylaxis is expected\\ud\nto be in the range \u00a338,000\u2013\u00a3428,000 per QALY gained\\ud\n(depending on subgroup). The cost-effectiveness\\ud\nratios for oseltamivir and zanamivir as post-exposure\\ud\nprophylaxis are expected to be below \u00a330,000 per\\ud\nQALY gained in healthy children, at-risk children, healthy\\ud\nelderly and at-risk elderly individuals. Despite favourable\\ud\nclinical efficacy estimates, the incorporation of recent\\ud\nevidence of viral resistance to amantadine led to it being\\ud\ndominated in every economic comparison.\\ud\nConclusions: All three interventions showed some\\ud\nefficacy for seasonal and post-exposure prophylaxis.\\ud\nHowever, weaknesses and gaps in the clinical evidence\\ud\nbase are directly relevant to the interpretation of\\ud\nthe health economic model and rendered the use of\\ud\nadvanced statistical analyses inappropriate. These data\\ud\nlimitations should be borne in mind in interpreting the findings of the review.Produced under the auspices of the NHS R & D Health Technology Assessment Programme. Monographs in this series are also available from the National Coordinating Centre for Health Technology Assessment (NCCHTA) website at www.ncchta.org.Peer reviewedPublisher versio","downloadUrl":"http:\/\/hdl.handle.net\/2381\/7750","fullTextIdentifier":"https:\/\/lra.le.ac.uk\/bitstream\/2381\/7750\/3\/mon1311%5b1%5d.pdf","pdfHashValue":"2ba1bbbab163b43434b37a94edb329df43d1cea6","publisher":"NHS NIHR Health Technology Assessment Programme","rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:lra.le.ac.uk:2381\/7750<\/identifier><datestamp>\n                2015-09-07T14:01:54Z<\/datestamp><setSpec>\n                com_2381_57<\/setSpec><setSpec>\n                com_2381_9550<\/setSpec><setSpec>\n                col_2381_58<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nAmantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation<\/dc:title><dc:creator>\nTappenden, Paul<\/dc:creator><dc:creator>\nJackson, R.<\/dc:creator><dc:creator>\nCooper, K.<\/dc:creator><dc:creator>\nRees, A.<\/dc:creator><dc:creator>\nSimpson, E.<\/dc:creator><dc:creator>\nRead, R.<\/dc:creator><dc:creator>\nNicholson, Karl G.<\/dc:creator><dc:description>\nObjectives: To evaluate the clinical effectiveness\\ud\nand incremental cost-effectiveness of amantadine,\\ud\noseltamivir and zanamivir for seasonal and postexposure\\ud\nprophylaxis of influenza.\\ud\nData sources: A MEDLINE search strategy was used\\ud\nand searches were carried out in July 2007.\\ud\nReview methods: An independent health economic\\ud\nmodel was developed based on a review of existing\\ud\ncost-effectiveness models and clinical advice. The model\\ud\ndraws together a broad spectrum of evidence relating\\ud\nto the costs and consequences associated with influenza\\ud\nand its prevention. Where direct evidence concerning\\ud\nthe effectiveness of prophylaxis within specific model\\ud\nsubgroups was lacking, the model uses estimates from\\ud\nmixed subgroups or extrapolates from other mutually\\ud\nexclusive subgroups.\\ud\nResults: Twenty-six published references relating to 22\\ud\nrandomised controlled trials (RCTs) were included in the\\ud\nclinical effectiveness review, along with one unpublished\\ud\nreport. Eight, six and nine RCTs were included for\\ud\namantadine, oseltamivir and zanamivir respectively.\\ud\nThe study quality was variable and gaps in the evidence\\ud\nbase limited the assessment of the clinical effectiveness\\ud\nof the interventions. For seasonal prophylaxis, there\\ud\nwas limited evidence for the efficacy of amantadine in\\ud\npreventing symptomatic, laboratory-confirmed influenza\\ud\n(SLCI) in healthy adults [relative risk (RR) 0.40, 95%\\ud\nconfidence interval (CI) 0.08\u20132.03]. Oseltamivir was\\ud\neffective in preventing SLCI, particularly when used in\\ud\nat-risk elderly subjects (RR 0.08, 95% CI 0.01\u20130.63).\\ud\nThe preventative efficacy of zanamivir was most notable\\ud\nin at-risk adults and adolescents (RR 0.17, 95% CI 0.07\u2013\\ud\n0.44), and healthy and at-risk elderly subjects (RR 0.20,\\ud\n95% CI 0.02\u20131.72). For post-exposure prophylaxis,\\ud\ndata on the use of amantadine were again limited: in\\ud\nadolescents an RR of 0.10 (95% CI 0.03\u20130.34) was\\ud\nreported for the prevention of SLCI. Oseltamivir was\\ud\neffective in households of mixed composition (RR\\ud\n0.19, 95% CI 0.08\u20130.45). The efficacy of zanamivir in\\ud\npost-exposure prophylaxis within households was also\\ud\nreported (RR 0.21, 95% CI 0.13\u20130.33). Interventions\\ud\nappeared to be well tolerated. Limited evidence was\\ud\navailable for the effectiveness of the interventions in\\ud\npreventing complications and hospitalisation and in\\ud\nminimising length of illness and time to return to normal\\ud\nactivities. No clinical effectiveness data were identified\\ud\nfor health-related quality of life or mortality outcomes.\\ud\nWith the exception of at-risk children, the incremental\\ud\ncost\u2013utility of seasonal influenza prophylaxis is expected\\ud\nto be in the range \u00a338,000\u2013\u00a3428,000 per QALY gained\\ud\n(depending on subgroup). The cost-effectiveness\\ud\nratios for oseltamivir and zanamivir as post-exposure\\ud\nprophylaxis are expected to be below \u00a330,000 per\\ud\nQALY gained in healthy children, at-risk children, healthy\\ud\nelderly and at-risk elderly individuals. Despite favourable\\ud\nclinical efficacy estimates, the incorporation of recent\\ud\nevidence of viral resistance to amantadine led to it being\\ud\ndominated in every economic comparison.\\ud\nConclusions: All three interventions showed some\\ud\nefficacy for seasonal and post-exposure prophylaxis.\\ud\nHowever, weaknesses and gaps in the clinical evidence\\ud\nbase are directly relevant to the interpretation of\\ud\nthe health economic model and rendered the use of\\ud\nadvanced statistical analyses inappropriate. These data\\ud\nlimitations should be borne in mind in interpreting the findings of the review.<\/dc:description><dc:description>\nProduced under the auspices of the NHS R & D Health Technology Assessment Programme. Monographs in this series are also available from the National Coordinating Centre for Health Technology Assessment (NCCHTA) website at www.ncchta.org.<\/dc:description><dc:description>\nPeer reviewed<\/dc:description><dc:description>\nPublisher version<\/dc:description><dc:date>\n2010-03-31T15:19:35Z<\/dc:date><dc:date>\n2010-03-31T15:19:35Z<\/dc:date><dc:date>\n2009-02<\/dc:date><dc:type>\nArticle<\/dc:type><dc:identifier>\nHealth Technology Assessment, 2009, 13 (11), pp. 1-268.<\/dc:identifier><dc:identifier>\nhttp:\/\/www.hta.ac.uk\/project\/1686.asp<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/2381\/7750<\/dc:identifier><dc:identifier>\n10.3310\/hta13110<\/dc:identifier><dc:language>\nen<\/dc:language><dc:rights>\nCopyright 2009 Queen's Printer and Controller of HMSO.  HTA reports may be freely reproduced for the purposes of private research and study.<\/dc:rights><dc:publisher>\nNHS NIHR Health Technology Assessment Programme<\/dc:publisher>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":null,"language":null,"relations":[],"year":2009,"topics":[],"subject":["Article"],"fullText":null}